The SEC Wants to End the Baby Shelf Cap. Here Is What Is Proposed, What Is Not, and What Small-Cap Traders Should Watch

Proposed vs. published vs. in effect

A note on names: the SEC now publishes what used to be called “C&DIs” (Compliance and Disclosure Interpretations) under the label Corporation Finance Interpretations (CFIs). Many write-ups still say “C&DI.” The ATM item is Question 116.26 under Securities Act Forms.

The current cap in one paragraph

Under I.B.6, a listed company with less than $75 million of public float can still use Form S-3 for primary offerings, but the market value of securities it sells under that instruction in any rolling 12 months cannot exceed one-third of its public float. The float price can come from any date within 60 days before the sale. For the full mechanics and the other limits that stack on top (authorized shares, exchange rules, contract caps), learn them in the FennEdge dilution course, especially the lesson Capacity limits.

What the cap looks like inside a real filing

On August 17, 2026, Daré Bioscience (Nasdaq: DARE) filed a 424B5 prospectus supplement for an offering of 4,085,687 common shares and 293,894 pre-funded warrants at $1.37 per share ($1.3699 per pre-funded warrant). Unregistered Series A and Series B warrants were sold in a concurrent private placement.

The cover page states the baby shelf math directly:

• Non-affiliate shares: 15,187,913
• Price used: $2.17, the closing price on June 18, 2026, which the filing describes as a date within 60 days of the supplement
• Public float: 15,187,913 × $2.17 = $32,957,771 (matches the filing)
• One-third cap: $32,957,771 ÷ 3 = $10,985,924 (matches the filing)
• Prior I.B.6 sales in the past 12 months, excluding this offering: none, per the filing

Now the registered offering itself, computed from the cover figures:

• Shares: 4,085,687 × $1.37 = $5,597,391
• Pre-funded warrants: 293,894 × $1.3699 = $402,605
• Total: about $6.0 million, or roughly 55% of the stated one-third cap

Two details are worth noticing. First, the last reported price on August 13, 2026 was $1.37, while the float was computed at $2.17. At $1.37, the same 15,187,913 non-affiliate shares would be worth about $20.8 million, and one-third of that would be about $6.9 million. The 60-day window in Instruction 1 to I.B.6 is why the cap in a filing can be larger than a spot-price calculation suggests. Second, the private warrants are not offered under the prospectus, so they appear in a different part of the filing than the registered shares.

That cover paragraph is the trader-visible footprint of I.B.6. If the proposal is adopted as written, paragraphs like this would stop appearing, because the one-third cap would no longer exist.

The March 2026 staff interpretation (CFI 116.26)

The question addresses a common small-cap sequence:

1. A company has an effective Form S-3 and is eligible under I.B.1 (public float of $75 million or more), so it has no one-third cap.
2. It signs an ATM sales agreement with a named sales agent for an amount it “reasonably expected to offer and sell,” and files the prospectus supplement.
3. At its next Section 10(a)(3) update (typically tied to the annual report), its float is below $75 million. It can still use Form S-3, but now only under I.B.6.

The staff said it will not object if the company keeps selling the full amount covered by the prospectus supplement filed before the update, even if that amount exceeds the I.B.6 limit.

What it does not do, based on the question as written and the law-firm summaries we reviewed:

• It is not relief for a company that loses Form S-3 eligibility entirely. The hypothetical assumes the company remains I.B.6-eligible.
• It covers the amount in the supplement already on file. Summaries such as Dechert’s read it as not extending to a new supplement or an upsized program filed after the company becomes subject to I.B.6.
• It is a staff position. It can be revised, and it does not bind the Commission.

Why traders might care: before this interpretation, a company whose float dropped under $75 million could face a hard question at its 10-K about how much of an existing ATM it could still use. After it, an ATM supplement filed while the company was I.B.1-eligible may stay usable at its full stated size. In filings, that means the dollar figure on an older ATM supplement can remain the relevant ceiling even after the company’s own 10-K shows a sub-$75 million float. Check the date of the supplement against the date of the 10(a)(3) update.

What the May 2026 proposal would change

Based on the proposing release and the SEC fact sheet, the proposal would:

• Remove the one-year reporting seasoning requirement for Form S-3.
• Remove all Form S-3 transaction requirements, including the $75 million public float test in I.B.1 and the baby shelf instruction in I.B.6. An eligible issuer could register an unlimited amount for primary offerings.
• Keep the “current and timely” reporting requirement and add an “ineligible issuer” bar to Form S-3. That bar includes a newly defined “BSP issuer” (blank check companies, certain shell companies, and issuers in an offering of penny stock as defined in Exchange Act Rule 3a51-1, with a three-year look-back for some categories), plus certain issuers with recent fraud-related convictions, antifraud decrees, or stop orders. Whether any given listed small cap would fall into the penny-stock category is a legal determination under Rule 3a51-1, which has its own exclusions. We are not making that call here.
• Create “ELI” and “SELI” tiers. An Eligible Listed Issuer is Form S-3-eligible with common equity on a national exchange. A Seasoned ELI has also been reporting for at least 12 months. ELIs would get “pay-as-you-go” fee treatment and other benefits now limited to well-known seasoned issuers (WKSIs). SELIs would be eligible for automatic shelf registration, which is effective on filing.
• Define “trading market” for ATMs. Rule 415(a)(4) would specify that ATM offerings, primary or resale, must be into securities listed and traded on a national securities exchange or traded in a market the Commission designates.
• Leave the three-year life of a shelf unchanged (footnote 269 of the release).

The SEC’s own estimate, based on companies that filed a 10-K in 2024: 1,023 issuers that are now subject to the one-third limit would no longer face it, and 1,127 issuers that cannot use Form S-3 today could become eligible. Together that is 2,150 additional issuers with uncapped Form S-3 access. The release says these counts do not reflect every eligibility condition, such as timely filing.

What it could mean for small-cap dilution: the SEC’s own framing

The release does not promise a particular outcome, and neither do we. It does lay out both sides, and those are the variables traders can track.

Arguments that dilution terms could improve (release’s framing):

• Footnote 228 describes “extreme convertibles” sold under exemptions by issuers that cannot use Form S-3 or run ATMs, often converting at steep discounts. The release suggests broader Form S-3 access may reduce the need for them.
• The economic analysis cites research that after the 2007 baby shelf changes, affected small issuers saw smaller offering discounts and moved away from PIPEs, with registered direct offerings removing an “illiquidity penalty.” Per the release, among companies with $10 million to $70 million of float, the share of their equity offerings that were registered rose from 30% in 2007 to 85% in 2008.
• Footnote 580 says that lower discounts mean fewer new shares for the same proceeds.

Arguments that dilution could become more frequent (also the release’s framing):

• The same footnote 580 says shelf offerings “may increase the frequency of offerings.”
• The cost discussion says some issuers “may exploit expanded Form S-3 eligibility to place more offerings that lead to excessive share dilution,” and that lower barriers make dilutive issuances more likely.
• Less staff review applies to shelf takedowns than to Form S-1 offerings.

Mapping that onto what traders see:

• ATM size. Today, a baby shelf issuer’s ATM supplement is usually sized to one-third of float less prior sales; Beasley Broadcast’s June 2026 ATM supplement, for example, was sized at $5,235,810 against a stated float of $15,707,434, which is one-third of that float. Without I.B.6, the supplement amount would be set by the company and its agent, not by a float formula. Read the stated dollar amount in each supplement rather than assuming a float-based cap.
• Shelf capacity math. The “one-third of float minus 12-month sales” calculation that traders run today would no longer apply to newly uncapped issuers. Other gates would still matter: the registered amount on the shelf, authorized but unissued shares, exchange shareholder-approval thresholds, and contract terms such as ownership blockers.
• Warrants and registered directs. Today, part of the reason deals pair registered shares with unregistered warrants is that registered capacity is scarce. Without the cap, more of a deal could be registered off the shelf. Whether issuers actually change structure is an open question; watch the cover pages.
• Speed. A SELI’s automatic shelf is effective on filing. For those issuers, the gap between “new S-3 filed” and “S-3 effective,” which traders sometimes treat as a lead time, could shrink to zero.

None of this is a forecast. The final rule, if any, may differ from the proposal.

What would not change

• Exchange listing rules. Nasdaq’s and NYSE American’s shareholder-approval thresholds are exchange rules, not Form S-3 conditions. The fact sheet does not describe changes to them.
• Authorized shares. A company still cannot issue shares its charter does not authorize.
• Contract limits. Ownership blockers, lock-ups, and variable-rate-transaction bans in purchase agreements still apply.
• Disclosure. Takedowns still require prospectus supplements filed under Rule 424(b), and 8-Ks still report material agreements.

What to watch in filings while the proposal is pending

1. 424B5 cover paragraphs. Look for the I.B.6 statement: non-affiliate shares, the price and its date, the one-third figure, and prior 12-month sales. Compare the price date with the current price.
2. ATM supplement dates vs. 10-K dates. Under CFI 116.26, the relevant ATM capacity may come from a supplement filed before the float fell below $75 million.
3. Withdrawn or replaced S-3s. An RW (registration withdrawal) for an S-3 followed by an S-1 can indicate that the company could not, or chose not to, use Form S-3. Check the filings for the stated reason rather than assuming one.
4. SEC rulemaking page and press releases. An adopting release would state an effective date and any transition rules. The proposal asks whether to provide a transition period for issuers that would lose eligibility.
5. Company comment letters and risk factors. Some issuers mention the proposal in risk factors or MD&A. Treat those as company statements, not as SEC decisions.

Bottom line

As of October 5, 2026, the baby shelf limit is still the law, CFI 116.26 is a published staff position that can preserve an existing ATM supplement’s size, and the Registered Offering Reform proposal is still only a proposal. The trader-useful habit stays the same either way: read the cover page of every takedown, write down the dollar ceiling and its date, and note which gate is the narrowest.

This article is for information and education. It is not investment, legal, or tax advice, and it does not recommend any security or trade.

Related reading

To keep checking related concepts, read Shelf registration, S-3, ATM and baby shelf, ATM offerings, Offerings, dilution and reverse splits, Registered directs: the Beasley Broadcast case; the FennEdge dilution course; and the trading glossary.

Sources

• SEC, Registered Offering Reform proposing release, Rel. No. 33-11418 (May 19, 2026)
• SEC, Rulemaking page, File No. S7-2026-17
• SEC, Fact sheet
• SEC, Press release 2026-46
• SEC, Press release index (checked through Oct 1, 2026)
• SEC, Corporation Finance Interpretations, Securities Act Forms, Question 116.26 (March 19, 2026)
• SEC, Form S-3 General Instructions
• Daré Bioscience, Form 424B5 (filed Aug 17, 2026)
• Beasley Broadcast Group, ATM prospectus supplement, Form 424B5 (filed June 12, 2026)
• Skadden, summary of the proposal (May 2026)
• Dechert, summary of CFI 116.26 (March 2026)